Lantern Pharma Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $4.22
- Today's High:
- $4.46
- Open Price:
- $4.46
- 52W Low:
- $4.05
- 52W High:
- $6.2
- Prev. Close:
- $4.39
- Volume:
- 27892
Company Statistics
- Market Cap.:
- $50.65 million
- Book Value:
- 4.44
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -16.39%
- Return on Equity TTM:
- -26.08%
Company Profile
Lantern Pharma Inc had its IPO on 2020-06-11 under the ticker symbol LTRN.
The company operates in the Healthcare sector and Biotechnology industry. Lantern Pharma Inc has a staff strength of 22 employees.
Stock update
Shares of Lantern Pharma Inc opened at $4.46 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $4.22 - $4.46, and closed at $4.24.
This is a -3.42% slip from the previous day's closing price.
A total volume of 27,892 shares were traded at the close of the day’s session.
In the last one week, shares of Lantern Pharma Inc have slipped by -9.01%.
Lantern Pharma Inc's Key Ratios
Lantern Pharma Inc has a market cap of $50.65 million, indicating a price to book ratio of 0.9933 and a price to sales ratio of 0.
In the last 12-months Lantern Pharma Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-15435464. The EBITDA ratio measures Lantern Pharma Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Lantern Pharma Inc’s operating margin was 0% while its return on assets stood at -16.39% with a return of equity of -26.08%.
In Q2, Lantern Pharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Lantern Pharma Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.27 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Lantern Pharma Inc’s profitability.
Lantern Pharma Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.0633. Its price to sales ratio in the trailing 12-months stood at 0.
Lantern Pharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $51.43 million
- Total Liabilities
- $3.02 million
- Operating Cash Flow
- $-457243.00
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Lantern Pharma Inc ended 2024 with $51.43 million in total assets and $0 in total liabilities. Its intangible assets were valued at $51.43 million while shareholder equity stood at $48.26 million.
Lantern Pharma Inc ended 2024 with $0 in deferred long-term liabilities, $3.02 million in other current liabilities, 1087.00 in common stock, $-47897033.00 in retained earnings and $0 in goodwill. Its cash balance stood at $28.42 million and cash and short-term investments were $47.95 million. The company’s total short-term debt was $163,146 while long-term debt stood at $0.
Lantern Pharma Inc’s total current assets stands at $51.04 million while long-term investments were $0 and short-term investments were $19.53 million. Its net receivables were $0 compared to accounts payable of $2.85 million and inventory worth $0.
In 2024, Lantern Pharma Inc's operating cash flow was $-457243.00 while its capital expenditure stood at $0.
Comparatively, Lantern Pharma Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $4.24
- 52-Week High
- $6.2
- 52-Week Low
- $4.05
- Analyst Target Price
- $20.5
Lantern Pharma Inc stock is currently trading at $4.24 per share. It touched a 52-week high of $6.2 and a 52-week low of $6.2. Analysts tracking the stock have a 12-month average target price of $20.5.
Its 50-day moving average was $4.74 and 200-day moving average was $5.11 The short ratio stood at 3.8 indicating a short percent outstanding of 0%.
Around 1746.7% of the company’s stock are held by insiders while 2452% are held by institutions.
Frequently Asked Questions About Lantern Pharma Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma. In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company’s artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.